Osteopore Ltd. (ASX:OSX) Filings

Osteopore Ltd.

Filings

FilingDateTypeFiled with
OSX focuses on Ortho line in Singapore via direct sellingNov 1, 2026Operations updateASX
Activities Report September 2026 and Appendix 4COct 30, 2026Quarterly reportASX
Resignation and appointment of Company SecretaryOct 2, 2026Management or board changeASX
OSX secures market access to Thailand orthopaedic marketSep 8, 2026Operations updateASX
Half Yearly Report and AccountsAug 31, 2026Interim reportASX
OSX strikes orthopaedic deal for 5 Middle East countriesAug 5, 2026Acquisition or disposalASX
Details of Auditor Appointment/ResignationAug 3, 2026Other filingsASX
OSX completes first Hainan custom orthopaedic implantAug 2, 2026Operations updateASX
Activities Report June 2026 and Appendix 4CJul 30, 2026Quarterly reportASX
OSX secures Hainan FDA approval for orthopaedic devicesMay 25, 2026Operations updateASX
Activities Report March 2026 and Appendix 4CApr 29, 2026Quarterly reportASX
Further Drawdown of T2 of the Redeemable Convertible NotesMar 26, 2026FinancingASX
Clarification - agreement for injectable regen bone fillerMar 12, 2026Operations updateASX
OSX signs agreement for injectable regenerative bone fillerMar 11, 2026Operations updateASX
OSX secures distribution for autologous dentin bone graftMar 2, 2026Operations updateASX
Appendix 4E Preliminary Final ReportFeb 27, 2026Annual reportASX
Drawdown of Tranche 2 of the Redeemable Convertible NotesFeb 16, 2026FinancingASX
OSX secures Latin America deal for craniofacial distributionFeb 12, 2026Operations updateASX
Further Drawdown of T1 of the Redeemable Convertible NotesFeb 6, 2026FinancingASX
Activities Report December 2025 and Appendix 4CJan 29, 2026Quarterly reportASX
Clarification - agreement for orthopaedic products in HKJan 22, 2026Other filingsASX
OSX strikes agreement for orthopaedic products in Hong KongJan 21, 2026Operations updateASX
Clarification - OSX partner Chinese dental & maxillofacialJan 16, 2026Operations updateASX
OSX partners up for Chinese dental & maxillofacial marketJan 15, 2026Acquisition or disposalASX
OSX partners DKSH for dental products in MalaysiaNov 24, 2025Operations updateASX
Activities Report September 2025 and Appendix 4COct 30, 2025Quarterly reportASX
OSX collaborates with TTSH to develop novel implant for AVNSep 8, 2025Operations updateASX
OSX Invests AUD 0.5m in Cellular Regenerative MedicineAug 31, 2025Operations updateASX
Half Yearly Report and AccountsAug 29, 2025Interim reportASX
OSX ortho product successful in Vietnam hospital tender bidsAug 3, 2025Operations updateASX
Activities Report June 2025 and Appendix 4CJul 30, 2025Quarterly reportASX
Business progress update, Zimmer Biomet sales units grows 3xJul 28, 2025Operations updateASX
Osteopore gains access to SwitzerlandJul 13, 2025Operations updateASX
Activities Report March 2025 and Appendix 4CApr 28, 2025Quarterly reportASX
Osteopore secures EU market approvals for custom implantsApr 8, 2025Operations updateASX
Reinstatement to QuotationApr 7, 2025Trading halt or suspensionASX
Suspension from QuotationMar 31, 2025Trading halt or suspensionASX
Convertible Note ProspectusMar 28, 2025FinancingASX
Drawdown of Tranche 1 of the Redeemable Convertible NotesFeb 14, 2025FinancingASX
Activities Report December 2024 and Appendix 4CJan 30, 2025Quarterly reportASX
OSX enters agreement to issue redeemable convertible notesDec 24, 2024FinancingASX
OSX partners scientists to drive regeneration innovationNov 3, 2024Operations updateASX
Activities Report September 2024 and Appendix 4COct 30, 2024Quarterly reportASX
Osteopore to raise A$20m via redeemable convertible noteSep 26, 2024FinancingASX
OSX and University of Chile complete bone implant studiesAug 21, 2024Operations updateASX
Activities Update Qtr Ending June 2024 and Appendix 4CJul 30, 2024Quarterly reportASX
Osteopore strikes Exclusive Distribution with Zimmer BiometJul 15, 2024Other filingsASX
A$18.7m Osteopore, NDCS and A*STAR project hits milestonesJun 5, 2024Operations updateASX
OSX and SingHealth partner on Global Centre of ExcellenceMay 13, 2024Operations updateASX
Osteopore successfully raises A$2.9m from Entitlement OfferMay 7, 2024FinancingASX
Activities Update Qtr Ending March 2024 and Appendix 4CApr 29, 2024Quarterly reportASX
Response to ASX Price and Volume QueryApr 23, 2024Explanation requestASX
Trading HaltApr 23, 2024Trading halt or suspensionASX
Pause in TradingApr 23, 2024Trading halt or suspensionASX
Reinstatement to Official QuotationApr 16, 2024Trading halt or suspensionASX
Response to ASX Query LetterApr 15, 2024Explanation requestASX
Osteopore extends Bridging Loan maturity dateApr 10, 2024FinancingASX
Replacement Prospectus for Renounceable Rights IssueApr 4, 2024Offer documentASX
Update to Replacement Prospectus for Entitlement OfferApr 3, 2024Offer documentASX
Osteopore secures Singapore and Vietnam market approvalsMar 26, 2024Operations updateASX
Prospectus for Renounceable Rights IssueMar 12, 2024Offer documentASX
OSX Entitlement Offer to support growthMar 12, 2024FinancingASX
Activities Update Qtr Ending December 2023 and Appendix 4CJan 30, 2024Quarterly reportASX
Notice of General MeetingJan 23, 2024Meeting noticeASX
Osteopore signs Bridging Loan agreementDec 28, 2023FinancingASX
Activities Update Qtr Ending September 2023 and Appendix 4COct 30, 2023Quarterly reportASX
MOU with Temasek-linked Innoventures - Orthopaedics in ChinaSep 11, 2023Other filingsASX
Activities Update Qtr Ending June 2023 and Appendix 4CJul 30, 2023Quarterly reportASX
OSX receives A$10m commitment for commercialisation in ChinaJul 24, 2023Other filingsASX
Osteopore strengthens Board & Management by key appointmentsJul 17, 2023Other filingsASX
Strategic Partnership for Clinical R&D in China worth $4MJun 7, 2023Other filingsASX
Largest South African Medical Insurer provides cover for OSXMay 15, 2023Other filingsASX
Activities Update Qtr Ending March 2023 and Appendix 4CApr 27, 2023Quarterly reportASX
OSX Successfully transitions to EU Medical Device RegulationApr 26, 2023Other filingsASX
Reinstatement of Security Class to QuotationApr 25, 2023Other filingsASX
Security Class Suspension from QuotationApr 24, 2023Trading halt or suspensionASX
Non-Renounceable Entitlement Offer - ResultsApr 24, 2023FinancingASX
OSX Strengthens Presence in the Eastern Region of the USAApr 10, 2023Other filingsASX
OSX Completes Acquisition to Accelerate Revenue GrowthMar 30, 2023Acquisition or disposalASX
Non-Renounceable Entitlement Offer ProspectusMar 12, 2023FinancingASX
Non-Renounceable Entitlement OfferMar 12, 2023FinancingASX
Activities Update Qtr Ending December 2022 and Appendix 4CJan 30, 2023Quarterly reportASX
Integration of Acquired Business for Higher Sales & MarginJan 22, 2023Acquisition or disposalASX
Firm Commitments and Non-Binding Proposed AcquisitionDec 21, 2022Acquisition or disposalASX
Suspension from Official QuotationDec 20, 2022Trading halt or suspensionASX
Increased presence and commercial opportunities across SEADec 7, 2022Other filingsASX
Activities Update Qtr Ending September 2022 and Appendix 4COct 30, 2022Quarterly reportASX
Osteopore Moves Closer to China Market EntryAug 22, 2022Other filingsASX
Activities Update Qtr Ending June 2022 and Appendix 4CJul 25, 2022Quarterly reportASX
OSX Enter Oral & Maxillofacial Market in Australia & NZMay 10, 2022Other filingsASX
Activities Update Qtr Ending March 2022 and Appendix 4CApr 28, 2022Quarterly reportASX
SHG: & CSIRO AI Tool to Optimise Cranial Implant ProceduresMar 13, 2022Other filingsASX
Activities Update Qtr Ending December 2021 and Appendix 4CJan 27, 2022Quarterly reportASX
Osteopore secures A$19m clinical-industrial partnershipDec 13, 2021Other filingsASX
Activities Update Qtr Ending September 2021 and Appendix 4COct 29, 2021Quarterly reportASX
SHG: CSIRO Collaboration for AI-based ToolOct 18, 2021Other filingsASX
Activities Update Qtr Ending June 2021 and Appendix 4CJul 30, 2021Quarterly reportASX
Activities Update Qtr Ending March 2021 and Appendix 4CApr 30, 2021Quarterly reportASX
Agreement with Terumo Blood and Cell TechnologiesJan 31, 2021Other filingsASX
Activities Update Qtr Ending December 2020 and Appendix 4CJan 29, 2021Quarterly reportASX
OSX Signs Australian & New Zealand Distribution AgreementOct 30, 2020Other filingsASX
Activities Update Qtr Ending September 2020 and Appendix 4COct 29, 2020Quarterly reportASX
Investor PresentationAug 21, 2020Other filingsASX
Osteopore Receives Binding Commitments for $8.5m PlacementAug 20, 2020FinancingASX
Activities Update Quarter Ending June 2020 and Appendix 4CJul 31, 2020Quarterly reportASX
Development of New 3D Printed Bone ImplantJul 22, 2020Other filingsASX
Clarification on Initial US Distribution AgreementJul 2, 2020Other filingsASX
Osteopore Signs Initial U.S. Distribution AgreementJul 1, 2020Other filingsASX
Activities Update Quarter Ending March 2020 and Appendix 4CApr 30, 2020Quarterly reportASX
Osteopore Receives Australian TGA ApprovalApr 19, 2020Other filingsASX
Pause In TradingApr 16, 2020Trading halt or suspensionASX
Company UpdateApr 8, 2020Other filingsASX
Company Update and Appendix 4CJan 30, 2020Quarterly reportASX
Former President and CEO of Cochlear Joins as Board AdvisorDec 3, 2019Other filingsASX
OSX Executes Memorandum of Co-operation in Hainan ProvinceNov 18, 2019Other filingsASX